Crude oil prices have surged to levels not seen since 2022, when geopolitical tensions escalated, impacting global markets significantly. This spike, with prices hovering around $99 per barrel, underscores the urgent need for the bioprocessing industry to address its reliance on fossil fuels. A recent report from F. Hoffmann-La Roche highlights that up to 60% of bioprocess raw materials may originate from fossil sources, with energy usage being a major contributor to fossil-derived impacts in biologic manufacturing.
As the industry grapples with rising petroleum costs, the call for defossilization becomes increasingly critical. Experts like Jan Backmann emphasize that pharmaceutical companies must integrate defossilization into their sustainability strategies. Some suppliers, such as Thermo Fisher Scientific, are already leading the way by offering biobased alternatives to traditional fossil-fuel feedstocks. However, until the industry can fully transition to sustainable practices, it must navigate the financial implications of fluctuating oil prices, which are unlikely to stabilize in the near future.
Use the database as your supply chain compass →
